[ad_1]
In a new study, WHO researchers have examined how different vaccine alternatives, including strade divir, have affected 11,266 COVID-19 patients who are being cared for in hospital.
The results show that none of the drugs improved the survival chances of the patients. It also did not decrease the need for a ventilator or the length of time patients required hospitalization.
“These methods of remdesivir, hydroxychloroquine, lopinavir, and interferon appear to have little effect on hospital mortality.“The study states, according to the Financial Times.
Sweden has received doses
The quality of the study has not yet been reviewed, but it may come as a severe blow to those who hoped the strap divider would aid in coronary care. Both the United States and the EU have been positive about the drug.
In early July, the European Commission approved the use of cordesivir for patients with a crown. Later, at the end of August, the first 1,700 doses were shipped to Sweden.
In total, the country had requested 70,000 doses for health aid.
– We have a favorable starting point with the number of patients needing a diveri belt at the moment. So our assessment is that those who need remdesivir will get it, said Maria State, then chief of the drug bureau for the National Board of Health and Welfare.
The response of the pharmaceutical company
Remdesivir is manufactured by the pharmaceutical company Gilead. In a comment to the Financial Times, the company writes that the preliminary results of the WHO study contradict “stronger evidence” coming from previous studies on the drug.
WHO has not commented on the study because it is not yet public.
The head of emergency preparedness for the National Board of Health and Welfare, Johanna Sandwall, has previously commented on strapsivir.
